Deanxit and Rivotril in Tinnitus Patients

University Hospital, Antwerp50 enrolled

Overview

The purpose of this study is to investigate whether increased tinnitus reduction can be obtained with Deanxit in patients already receiving Rivotril.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Tinnitus

Interventions

DeanxitDRUG

Deanxit 1x/day

Lactose placeboDRUG

Lactose used as placebo

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * pure tone, narrow band noise or polyphonic tinnitus * unilateral or bilateral tinnitus * VAS ≥ 4 * cochleair origin tinnitus * tinnitus present 3 months or more * age 18y or more * intake Rivotril 1mg/d * patient 'able to cooperate' * patient able to fill in TQ en VAS * No pontine angle pathology on MRI Exclusion Criteria: * pulsatile tinnitus * pregnancy or breast feeding * contra-indications Deanxit * recovery myocard infarct * conduction disorder His * untreated glaucoma * MAO inhibitors: 15d stop * otosclerosis * middle ear pathologies * Ménière * somatic tinnitus

Locations (1)

Antwerp University Hospital

Antwerp, Antwerp, Belgium

Outcomes

Primary Outcomes

Visual Analogue Scale

Time frame: 3 weeks, 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.